Raghu Tadagavadi
Executive Director, Nonclinical Development & Safety Century Therapeutics
Raghu Tadagavadi is Executive Director and Head of Nonclinical Development and Safety at Century Therapeutics. He previously held scientific roles at Johnson & Johnson, Legend Biotech, and Charles River Laboratories, where he contributed to the nonclinical development of small molecules, biologics, and cell therapies. Dr. Tadagavadi holds a BVSc and an MVSc in Immunology. He began his career as a clinical veterinarian and subsequently transitioned to immunology and toxicology following his PhD at Pennsylvania State University and postdoctoral work at Emory University. He is a Diplomate of the American Board of Toxicology (DABT) and holds a Regulatory Affairs Certification (RAC).
Seminars
- Evaluate in vitro discovery and investigative toxicology in cell therapy platforms to define target biology, evaluate therapeutic liabilities, and establish early human relevance
- Review fit-for-purpose in vivo models in cell therapies to integrate safety with efficacy, PK, and biodistribution, while acknowledging species differences and model limitations
- Discover a strategy integrating in vitro and in vivo data to address safety liabilities while leveraging efficacy strengths for a regulatory-aligned IND in cell therapy
